The effect of lanreotide on non-functioning pituitary macroadenoma size
Completed
- Conditions
- pituitary adenomahypofyse adenoom
- Registration Number
- NL-OMON27861
- Lead Sponsor
- Prof. dr. E. Fliers, Academic Medical Center, University of Amsterdam
- Brief Summary
https://bmjopen.bmj.com/content/10/8/e038250
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 44
Inclusion Criteria
Adult patients (>18 yrs)
Clinically non-functioning pituitary macroadenoma with suprasellar extension
Exclusion Criteria
Optic chiasm compression with visual field defects
Hypersensitivity for somatostatin or similar peptides
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in cranio-caudal NFMA size
- Secondary Outcome Measures
Name Time Method Adverse events (AE’s)<br /><br>Change in quality of life<br /><br>Change in NFMA volume